Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast for Central Centrifugal Cicatricial Alopecia
NCT03521687Phase 4Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Nov 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of apremilast in central centrifugal cicatricial alopecia (CCCA), sponsored by Icahn School of Medicine at Mount Sinai. Started Nov 2018; status: completed.
02
Drugs
apremilast
03
Conditions
central centrifugal cicatricial alopecia (CCCA)
Beyond the preview
Go deeper on NCT03521687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03521687.